5 July 2023 in The Annals of Thoracic Surgery
31 August 2024 in The Journal of Thoracic and Cardiovascular Surgery
30 October 2024 in JTCVS Open
Patients with cancer who receive radiation therapy to the thorax often develop radiation-induced heart disease (RIHD) decades later. Previous chest radiation is associated with elevated perioperative risk of complications and mortality after cardiac surgery. Whether the type of valve (mechanical vs bioprosthetic) used affects outcomes in patients with RIHD is unknown. This retrospective review analyzed the characteristics and postoperative outcomes of patients with a previous history of chest radiation for Hodgkin or non-Hodgkin lymphoma who underwent surgical valve replacement at a single institution between 2000 and 2021. Both 30-day perioperative outcomes and long-term survival were assessed. Patients who received mechanical valve tended to be younger, have more valves replaced, and have undergone previous coronary artery bypass grafting than bioprosthetic valve recipients. Valve type alone did not alter perioperative complications or overall survival. Median survival was 11.0 years in mechanical and 10.9 years in bioprosthetic valve patients (P = .930). Twelve patients underwent valve reinterventions (6 mechanical, 6 bioprosthetic), and 3 underwent transplant. Single-valve (aortic valve or mitral valve) recipients fared better with median survival of 13.3 years compared with 6.2 years in those who underwent combined aortic valve replacement plus mitral valve replacement (P < .0001). Patients with RIHD who undergo surgical valve replacement have similarly suboptimal short- and long-term outcomes regardless of mechanical versus bioprosthetic valve type. Those who required combined aortic and mitral valve replacement had especially high 10-year overall mortality. Further investigation in a larger dataset including transcatheter approaches is warranted.
5 August 2025 in Oral Oncology
17 August 2026 in Clinical Cancer Research
Purpose: Human papillomavirus (HPV)–associated carcinomas (HPV+ cancers) account for 5% of all cancers. Circulating tumor HPV DNA (ctHPVDNA) assays for HPV+ cancer surveillance have limited prognostic utility at the time of cancer diagnosis. Although HPV integration into the host genome is a proven tissue-based biomarker predicting poor clinical outcomes, existing clinically utilized ctHPVDNA assays cannot classify the viral physical state. Experimental Design: We previously developed HPV-DeepSeek, a multifeature HPV whole-genome sequencing liquid biopsy with 99% diagnostic accuracy at the time of HPV+ oropharyngeal cancer diagnosis. We tested the diagnostic accuracy of HPV-DeepSeek in a cohort of 235 HPV+ cancers across 9 anatomic sites and used a novel blood-based computational classifier to infer the HPV genome physical state from plasma, termed HPV sequencing-based integration analysis (HPV-SIGNAL), to assess its prognostic potential. Results: HPV-DeepSeek achieved 99% sensitivity and specificity. In 189 eligible samples, HPV-SIGNAL identified 4 viral physical states: episomal-only (n = 71), episomal-rearranged (n = 52), integrated-mixed (n = 57), and integrated-clonal (n = 9), which were confirmed and further elucidated via 3 orthogonal tissue and blood approaches. Patients harboring integrated viral states in blood exhibited significantly worse age-adjusted and American Joint Committee on Cancer stage–adjusted progression-free survival [PFS; HR, 2.78; 95% confidence interval (CI), 1.30–5.99; P = 0.009] and overall survival (OS; HR, 2.95; 95% CI, 1.01–8.61; P = 0.048) compared with patients with episomal states. Conclusions: HPV whole-genome sequencing liquid biopsy has high diagnostic accuracy across HPV+ cancer types and can be used to identify and classify HPV physical states from blood. Patients with integrated viral states detected in blood demonstrated worse PFS and OS, suggesting that blood-based HPV physical state classification could be used as a prognostic tool at the time of cancer diagnosis.